Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

A New Dawn in Ulcerative Colitis Care: Peptide-Assisted Antigen-Specific Immunotherapy | LifeTein Peptide Blog

The chronic autoinflammatory bowel disease ulcerative colitis affects millions around the world. The condition involves autoreactive T cells and macrophages in the colonic mucosa attacking healthy colon cells, leading to inflammation, ulcers, and other debilit

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

The chronic autoinflammatory bowel disease ulcerative colitis affects millions around the world. The condition involves autoreactive T cells and macrophages in the colonic mucosa attacking healthy colon cells, leading to inflammation, ulcers, and other debilitating symptoms and complications. While there is no outright cure, the only treatment involved is long-term immunosuppression, which can lead to even more health complications and risk of cancer down the line. One novel solution possible is antigen-specific immunotherapy, where the specific antigens are presented to the T cells in the presence of immunomodulators. Peptide-assisted antigen-specific Immunotherapy of ulcerative colitis by being adsorbed to nanofibers utilized in the colon-specific niche developed for this condition. Mimetic peptides utilized in antigen-specific immunotherapyLifeTein provided the group with the Cationic TGF-β1 mimetic peptide, whose role in the niche is to bind to a key receptor and suppress the activation of CD8+ T cells. This also polarizes the macrophages involved as well. The final results proved that not only could the auto reactive T cells be inhibited, but healthy colon cells could help repair previous damages of ulcerative colitis afterwards. All of this was achieved while actively avoiding the cancer risks of standard immunosuppressive approaches. Hopefully, this modular method can be pivotal in future developments for safer and more effective uses of immunotherapies.Kin Man Au, Justin E. Wilson, Jenny P.-Y. Ting, Andrew Z. Wang. An Injectable Subcutaneous Colon-Specific Immune Niche For The Treatment Of Ulcerative Colitis doi: https://doi.org/10.1101/2023.10.03.560652

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

Clinical Trials and Research

Several clinical trials have explored the use of PADRE in cancer vaccines. For instance, vaccines targeting Mucin 1 (MUC1), a glycoprotein overexpressed in many cancers, have shown promising results when combined with PADRE. These vaccines have demonstrated the ability to elicit strong immune responses, including the production of antibodies against cancer-specific antigens.

Source: lifetein.com ↗

In Vivo Studies and Therapeutic Development

For peptides intended for animal studies or clinical use, TFA poses safety and efficacy risks. Its toxicity profile includes organ toxicity and immunogenicity, potentially invalidating preclinical data. Regulatory guidelines for Active Pharmaceutical Ingredients (APIs) require TFA levels <0.1%, necessitating rigorous removal protocols like LifeTein’s TFA Salt Exchange.

Source: lifetein.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to solubilize my synthetic peptides? #

Please refer to this FAQ for details: Handling and Storage of Synthetic Peptides. If the peptides are still cloudy, or turbid, you may have reached the limit of solubility. When the peptides are insoluble in the buffer, please try to sonicate, centrifuge, and lyophilize the peptide. Make sure to break the lyophilized lumps into a fine powder. Then try a small volume of a good agent 8M Urea, NMP, DMF, or DMSO to dissolve the peptide. Then dilute with water or your desired buffer. For peptides with Arg or LYs, you should try to lower the pH to 6 because the protonated amino acids will help solubility. Sonication and the following solvents may help with difficult peptides: 1) Begin with 100 % acetonitrile then dilute with water until 50% 2) Begin with 100% DMSO then dilute with water until 30 % 3) Dissolve it with 8M Urea 4) Dissolve it with 6 or 8 M Guanidine hydrochloride 5) 6M GuHCL, 0.05% TFA, pH2, 6) 100% TFA 7) 40% AcOH, 30%ACN, 30% water

Source: lifetein.com ↗
Storage reference

Increased Stability and Reduced Immunogenicity

A significant barrier to the development of peptide therapeutics is their susceptibility to proteolytic degradation by ubiquitous enzymes in the bloodstream and tissues. The PEG chain, along with its associated water molecules, forms a protective shield around the peptide core, sterically hindering the access of proteases . This shield also masks antigenic determinants on the peptide’s surface, rendering it less recognizable to the immune system. This dual action of enhanced stability and reduced immunogenicity makes PEGylation a powerful tool for improving the drug-like properties of biologic therapies. Find more peptide modifications here.

Source: lifetein.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides